Monograph
J01XE01 - Nitrofurantoin |
Porphyrinogenic |
P |
Rationale
hydantoin derivative. Associated with attacks. Several references warn against it.
Chemical description
Nitrofuran derivative used in urinary tract infections. Between 30% and 50% of the dose is excreted in urine in unchanged form. No further data on metabolism or CYP interaction. Australian list: unsafe/attacks. South African list: use with extreme caution only. Tschudy, Lamon: 1980 potentially unsafe. Moore MR, Hift RJ 1997: potentially unsafe. Martindale: Considerd unsafe, associated with attacks.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Luxembourg
Iceland
Finland
Latvia
Serbia
